WO1997029745B1 - Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique - Google Patents

Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique

Info

Publication number
WO1997029745B1
WO1997029745B1 PCT/US1997/002270 US9702270W WO9729745B1 WO 1997029745 B1 WO1997029745 B1 WO 1997029745B1 US 9702270 W US9702270 W US 9702270W WO 9729745 B1 WO9729745 B1 WO 9729745B1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
group
zwitterion
mammal
compound
Prior art date
Application number
PCT/US1997/002270
Other languages
English (en)
Other versions
WO1997029745A1 (fr
Filing date
Publication date
Priority claimed from US08/600,901 external-priority patent/US5716959A/en
Application filed filed Critical
Priority to EA199800717A priority Critical patent/EA001929B1/ru
Priority to US08/983,269 priority patent/US6071919A/en
Priority to EP97907616A priority patent/EP0904073A4/fr
Priority to JP52947997A priority patent/JP3309990B2/ja
Priority to IL12577597A priority patent/IL125775A/en
Priority to AU19577/97A priority patent/AU700502B2/en
Publication of WO1997029745A1 publication Critical patent/WO1997029745A1/fr
Publication of WO1997029745B1 publication Critical patent/WO1997029745B1/fr

Links

Abstract

L'invention concerne un procédé de traitement d'une maladie affectant un animal, ce procédé consistant à administrer un composé zwitterion amphotère comme ingrédient actif. L'invention concerne également une composition pharmaceutique comprenant un composé zwitterion utilisé comme ingrédient actif en combinaison avec un excipient et autres agents pharmaceutiques adjoints.
PCT/US1997/002270 1996-02-13 1997-02-13 Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique WO1997029745A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EA199800717A EA001929B1 (ru) 1996-02-13 1997-02-13 Способ лечения заболеваний млекопитающих и цвиттерионная композиция
US08/983,269 US6071919A (en) 1996-02-13 1997-02-13 Zwitterionic compositions and methods as biological response modifiers
EP97907616A EP0904073A4 (fr) 1996-02-13 1997-02-13 Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique
JP52947997A JP3309990B2 (ja) 1996-02-13 1997-02-13 生物学的応答調節剤としての双性イオンの組成物及び方法
IL12577597A IL125775A (en) 1996-02-13 1997-02-13 Use of a zwitterion composition in the preparation of pharmaceutical compositions
AU19577/97A AU700502B2 (en) 1996-02-13 1997-02-13 Zwitterionic compositions and methods as biological response modifiers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/600,901 US5716959A (en) 1996-02-13 1996-02-13 Method of treating disease with piperazine zwitterion compounds
US08/600,901 1996-02-13

Publications (2)

Publication Number Publication Date
WO1997029745A1 WO1997029745A1 (fr) 1997-08-21
WO1997029745B1 true WO1997029745B1 (fr) 1997-09-25

Family

ID=24405525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002270 WO1997029745A1 (fr) 1996-02-13 1997-02-13 Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique

Country Status (8)

Country Link
US (2) US5716959A (fr)
EP (1) EP0904073A4 (fr)
JP (1) JP3309990B2 (fr)
AU (1) AU700502B2 (fr)
CA (1) CA2230639A1 (fr)
EA (1) EA001929B1 (fr)
IL (1) IL125775A (fr)
WO (1) WO1997029745A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
US6448251B1 (en) * 1997-11-28 2002-09-10 Peter T. Pugliese Zwitterionic-fatty acid compounds having anti-inflammatory properties
EP1033913A1 (fr) 1997-11-28 2000-09-13 Peter T. Pugliese Composes a base d'acide zwitterionique a proprietes anti-inflammatoires
DE69924146D1 (de) * 1998-12-21 2005-04-14 Inkeysa Sa Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
JP4698843B2 (ja) * 1999-05-17 2011-06-08 エーザイ インコーポレイテッド 生体活性剤の改良された細胞取り込み
AUPR626001A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method of treatment and/or prophylaxis
WO2004012662A2 (fr) * 2002-08-01 2004-02-12 Aesgen, Inc. Traitement ameliore du cancer avec la glutamine
US7592154B2 (en) * 2005-08-05 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Modulating SOS response induction by antimicrobial agents
SI22466A (sl) * 2007-03-14 2008-10-31 Romina Znoj Kombinacija, ki vsebuje rastlinske ekstrakte, in njena uporaba za zdravljenje različnih oblik raka
EP2440198B1 (fr) * 2009-06-09 2016-01-06 Cimas Limited Acides carboxyliques aliphatiques halogénés, oligomères et/ou polymères de ceux-ci et leur utilisation dans la dévitalisation de néoplasmes externes et internes
MX360190B (es) * 2009-09-17 2018-10-24 Bespoke Bioscience Llc Papel del acido n-2-hidroxi-etil-piperazina-n' -2-etano sulfonico (hepes) en el tratamiento de sintomas de abstinencia, efectos colaterales o ambos despues del tratamiento con anti-depresivos o inhibidores de serotonina selectiva (ssri).
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
AU2014206220B2 (en) * 2009-09-17 2016-09-29 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
US20140377814A1 (en) * 2012-02-07 2014-12-25 Industry-Academic Cooperation Foundation, Yonsei University Method For The Fixation Or Conversion Of High-Pressure Carbon Dioxide Using Barophilic Sulfur-Oxidizing Chemolithoautotrophs
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (fr) * 2018-07-31 2020-02-06 株式会社親広産業 Promoteur de la consommation de glucose et promoteur de glycolyse

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK227083D0 (da) * 1982-08-17 1983-05-20 Sullivan Donncha O Farmaceutisk komposition og fremgangsmade til dens fremstilling
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
IE853206L (en) * 1985-12-18 1987-06-18 Sullivan Donncha O Use of aminosulfonic acids in treatment of inflammatory¹conditions
GB8713091D0 (en) * 1987-06-04 1987-07-08 Millrine W P Pharmaceutical compositions
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
AU9805998A (en) * 1997-10-15 1999-05-03 T. Ronald Theodore Zwitterionic compositions and methods as biological response modifiers
EP1033913A1 (fr) * 1997-11-28 2000-09-13 Peter T. Pugliese Composes a base d'acide zwitterionique a proprietes anti-inflammatoires

Similar Documents

Publication Publication Date Title
WO1997029745B1 (fr) Procedes et compositions zwitterioniques utilisees comme modificateurs de reponse biologique
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
HK1035336A1 (en) Use of preparations for the application of antiseptic agents and/or agents promoting the healing of wounds to the lower respiratory tract
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
EP0333606A3 (en) Preparation of t-cell and t-cell membrane for use in prevention and treatment of autoimmune diseases
EP0251494A3 (en) System for administering therapeutic or radiodiagnostic compound
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
EP0328924A3 (fr) Composés de thiénotriazolodiazépine et ses applications pharmaceutiques
CA2091134C (fr) Agent therapeutique contre les risques d'avortement
EP0410749A3 (en) Anthocyanidins for the treatment of ophthalmic diseases
IE892261L (en) Therapeutic compounds
EP0175440A3 (fr) Procédé de traitement de maux de tête dus à la migraine
JPS6471814A (en) Useikokashooshochisurutamenoiyakusoseibutsu
尹莹 Blood-letting at a single point for treatment of acute diseases
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
Eickenberg Interstitial concentration of antibiotics and their significance for an adequate dosage
BR0107211A (pt) Agente para tratar hepatite c
AU1494395A (en) The use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases
IT8567191A1 (it) Composto steroide farmaceuticamente attivo procedimento per le sua preparazione e composizioni farmaceutiche che lo comprendono.
WO1996020702B1 (fr) Utilisation d'acide 2,3-alkylcarbonyloxybenzoique pour traiter le syndrome de souffrance respiratoire chez l'adulte
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa